Experienced in Transient Global Amnesia

Dr. Richard F. Holub

Albany, NY
Experienced
in Transient Global Amnesia
Specialties:Neurology
OverviewInsuranceLocationsClinical Research

Overview

Richard Holub is a Neurologist in Albany, New York. Dr. Holub and is rated as an Experienced provider by MediFind in the treatment of Transient Global Amnesia. His top areas of expertise are Cerebellar Degeneration, Memory Loss, Benign Rolandic Epilepsy, and Seizures.

His clinical research consists of participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in NY
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

760 Madison Ave, Albany, NY 12208
518-449-2662

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: February 05, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 15, 2024
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing Safety, Tolerability and Long-term Efficacy of Bryostatin in the Treatment of Moderately Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing Safety, Tolerability and Long-term Efficacy of Bryostatin in the Treatment of Moderately Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Enrollment Status: Completed
Publish Date: July 31, 2024
Intervention Type: Drug, Other
Study Drug: Bryostatin I
Study Phase: Phase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 17, 2024
Intervention Type: Drug
Study Drug: AGB101
Study Phase: Phase 2/Phase 3
A Randomized, Placebo-Controlled, Translational Study of ATH-1017 in Subjects With Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Translational Study of ATH-1017 in Subjects With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: June 12, 2023
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 23, 2023
Intervention Type: Drug
Study Drug: COR388
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Enrollment Status: Completed
Publish Date: October 01, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
View 9 Less Clinical Trials
Similar Doctors
Expertise in
17
conditions
Dr. Paul M. Deringer
Neurology
Expertise in
17
conditions
Dr. Paul M. Deringer
Neurology

Mary Imogene Bassett Hospital

1 Atwell Rd, 
Cooperstown, NY 
 (58.2 mi)
Languages Spoken:
English

Paul Deringer is a Neurologist in Cooperstown, New York. Dr. Deringer and is rated as a Distinguished provider by MediFind in the treatment of Transient Global Amnesia. His top areas of expertise are Epilepsy, Seizures, Memory Loss, and Migraine.

Expertise in
21
conditions
Dr. Konstantin Timofeev
Neurology
Expertise in
21
conditions
Dr. Konstantin Timofeev
Neurology

Albany Medical College

43 New Scotland Ave, 
Albany, NY 
 (0.4 mi)
518-262-3277
Languages Spoken:
English
See accepted insurances

Konstantin Timofeev is a Neurologist in Albany, New York. Dr. Timofeev and is rated as an Advanced provider by MediFind in the treatment of Transient Global Amnesia. His top areas of expertise are Migraine, Memory Loss, Seizures, and Epilepsy.

Expertise in
12
conditions
Dr. Syed F. Sher
Neurology
Expertise in
12
conditions
Dr. Syed F. Sher
Neurology

Mary Imogene Bassett Hospital

1 Atwell Rd, 
Cooperstown, NY 
 (58.2 mi)
607-547-3480
Languages Spoken:
English
Offers Telehealth

Syed Sher is a Neurologist in Cooperstown, New York. Dr. Sher and is rated as an Advanced provider by MediFind in the treatment of Transient Global Amnesia. His top areas of expertise are Epilepsy, Seizures, Memory Loss, and Headache.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile